Piper Jaffray Companies restated their overweight rating on shares of Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) in a report published on Wednesday morning. Piper Jaffray Companies currently has a $30.00 price target on the specialty pharmaceutical company’s stock.

ADMS has been the subject of several other research reports. JMP Securities restated an outperform rating and set a $33.00 price objective (up previously from $29.00) on shares of Adamas Pharmaceuticals in a report on Friday, August 25th. Zacks Investment Research downgraded Adamas Pharmaceuticals from a hold rating to a sell rating in a report on Friday, August 11th. BidaskClub upgraded Adamas Pharmaceuticals from a strong sell rating to a sell rating in a report on Wednesday, August 23rd. ValuEngine upgraded Adamas Pharmaceuticals from a sell rating to a hold rating in a report on Friday, September 1st. Finally, Cowen and Company set a $45.00 price objective on Adamas Pharmaceuticals and gave the company a buy rating in a report on Wednesday, August 9th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the stock. Adamas Pharmaceuticals currently has an average rating of Buy and a consensus price target of $39.50.

Shares of Adamas Pharmaceuticals (ADMS) traded up 7.09% during trading on Wednesday, hitting $23.71. 1,132,106 shares of the stock traded hands. The firm’s market cap is $533.81 million. Adamas Pharmaceuticals has a 52 week low of $12.10 and a 52 week high of $24.18. The company has a 50-day moving average of $19.73 and a 200-day moving average of $17.53.

Adamas Pharmaceuticals (NASDAQ:ADMS) last released its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.93) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.81) by ($0.12). The firm had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.03 million. The firm’s quarterly revenue was down 90.9% on a year-over-year basis. During the same period last year, the company posted ($0.78) EPS. On average, analysts forecast that Adamas Pharmaceuticals will post ($3.77) EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This story was first published by Marea Informative and is owned by of Marea Informative. If you are reading this story on another website, it was stolen and reposted in violation of US and international copyright and trademark legislation. The legal version of this story can be read at http://www.mareainformativa.com/adamas-pharmaceuticals-inc-adms-receives-overweight-rating-from-piper-jaffray-companies/117687/.

Institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. grew its holdings in Adamas Pharmaceuticals by 10.3% during the first quarter. Vanguard Group Inc. now owns 716,419 shares of the specialty pharmaceutical company’s stock worth $12,537,000 after buying an additional 66,825 shares in the last quarter. Goldman Sachs Group Inc. grew its holdings in Adamas Pharmaceuticals by 212.9% during the first quarter. Goldman Sachs Group Inc. now owns 60,897 shares of the specialty pharmaceutical company’s stock worth $1,066,000 after buying an additional 41,436 shares in the last quarter. Emerald Advisers Inc. PA grew its holdings in Adamas Pharmaceuticals by 2.7% during the second quarter. Emerald Advisers Inc. PA now owns 532,727 shares of the specialty pharmaceutical company’s stock worth $9,317,000 after buying an additional 14,042 shares in the last quarter. Geode Capital Management LLC grew its holdings in Adamas Pharmaceuticals by 4.9% during the first quarter. Geode Capital Management LLC now owns 125,793 shares of the specialty pharmaceutical company’s stock worth $2,201,000 after buying an additional 5,920 shares in the last quarter. Finally, Granite Point Capital Management L.P. grew its holdings in Adamas Pharmaceuticals by 11.9% during the second quarter. Granite Point Capital Management L.P. now owns 263,515 shares of the specialty pharmaceutical company’s stock worth $4,609,000 after buying an additional 28,000 shares in the last quarter. Institutional investors and hedge funds own 69.31% of the company’s stock.

About Adamas Pharmaceuticals

Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.

Analyst Recommendations for Adamas Pharmaceuticals (NASDAQ:ADMS)

Receive News & Stock Ratings for Adamas Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.